{
    "2019-08-08": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Momenta Continues Its Transition",
                "features": {
                    "keywords": [
                        "Momenta",
                        "transition"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Sarepta stock tumbles after Duchenne gene therapy complication",
                "features": {
                    "keywords": [
                        "Sarepta",
                        "tumbles",
                        "Duchenne",
                        "gene therapy",
                        "complication"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "NVS vs. NVO: Which Stock Should Value Investors Buy Now?",
                "features": {
                    "keywords": [
                        "NVS",
                        "NVO",
                        "value investors",
                        "buy"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-12",
                "original_text": "Medicare to cover expensive cancer cell therapies",
                "features": {
                    "keywords": [
                        "Medicare",
                        "cover",
                        "cancer",
                        "cell therapies"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-05",
                "original_text": "Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS)",
                "features": {
                    "keywords": [
                        "Glancy Prongay & Murray LLP",
                        "Investigation",
                        "Novartis",
                        "investors"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "legal",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-08-15",
                "original_text": "2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond",
                "features": {
                    "keywords": [
                        "Marijuana",
                        "stocks",
                        "Q2 earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}